APIXABAN – FROM RECOMMENDATIONS TO EVERYDAY PRACTICE

Abstract

The articles deals with the analysis of clinical situations in patients with atrial fibrillations in the aspect of choice of the anticoagulant therapy with apixaban use in relation with the recent (2015) recommendations of the European Heart Rhythm Association. The authors conduct analysis of necessity and possibility to use the oral anticoagulant apixaban to prevent stroke in patients with non-valvular atrial fibrillation. On the whole, new oral anticoagulants exceed the warfarin therapy in he capability to reduce the risk of thrombolytic complications and iatrogenic hemorrhagic stroke in patients with non-valvular atrial fibrillations. The article demonstrates justification of situations of predominant apixaban selection in certain clinical settings.

Keywords

• atrial fibrillation
• stroke
• warfarin
• new oral anticoagulants
• apixaban